US equities |
AAPL $332.27 ▼-1.79% MU $851.87 ▲+2.19% NVDA $208.34 ▲+3.11% AMD $491.85 ▲+5.36% SPCX $141.56 ▲+3.81% ORCL $127.59 ▲+7.02% PLTR $174.69 ▼-2.04% SNDK $1,112.52 ▲+3.48%
FinancialContent

CareDx, Inc. - Common Stock (NQ:CDNA)

88.82 +2.94 (+3.42%)
Delayed Quote Updated: 1:16 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CareDx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
CareDx (NASDAQ:CDNA): A Case for Affordable Growth ↗
Via Chartmill
News headline image
CareDx Announces Third KOAR Analysis Published in Transplantation
From CareDx, Inc.
Via Business Wire
News headline image
Why CareDx Stock Soared Today ↗
The precision medicine pioneer is helping to improve patient care. 
Via The Motley Fool
Gap-Up and Gap-Down Stocks for October 30, 2026 ↗
Via Chartmill
News headline image
CareDx (CDNA) Q3 2026 Earnings Call Transcript ↗
Testing volumes surged 51% as NavDx integration drove revenue and margin gains. 
Via The Motley Fool
Topics Earnings
CareDx (NASDAQ:CDNA): Strong Growth Meets Technical Setup Quality ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Stands Out for High Growth and Improving Fundamentals ↗
Via Chartmill
CAREDX INC (NASDAQ:CDNA): High Growth and Improving Fundamentals Fuel Bullish Case ↗
Via Chartmill
News headline image
What CareDx (CDNA) Said on Its Q3 Earnings Call ↗
CareDx (NASDAQ:CDNA) reported third-quarter 2026 revenue growth of 39% as testing volumes increased, driven by its transplant business and the addition of Specialty Oncology testing following the July... 
Via MarketBeat
Topics Earnings
After-Hours Market Movers: Oct. 29, 2026 Gainers and Losers ↗
Via Chartmill
News headline image
CareDx Announces Third Quarter 2026 Financial Results
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
From CareDx, Inc.
Via Business Wire
CareDx (NASDAQ:CDNA) Meets Minervini Trend Template with High-Growth Momentum ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Screens Well on High Growth Momentum and Breakout Setup ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Shows Strong Growth Fundamentals by Passing All Eight Rules of Navellier's Screen ↗
Via Chartmill
CareDx (NASDAQ:CDNA) Combines Strong Growth With a Bullish Technical Setup ↗
Via Chartmill
News headline image
CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
From CareDx, Inc.
Via Business Wire
CareDx (NASDAQ:CDNA) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
CareDx (NASDAQ:CDNA) Posts Accelerating Growth and Strengthening Fundamentals ↗
Via Chartmill
News headline image
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CareDx, Inc.
Via Business Wire
News headline image
Why CareDx Stock Jumped Today ↗
The diagnostics leader is accelerating the trend toward precision medicine. 
Via The Motley Fool
News headline image
CareDx Q2 Earnings Call Highlights ↗
CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began... 
Via MarketBeat
Topics Earnings
News headline image
CareDx Announces Second Quarter 2026 Financial Results
From CareDx, Inc.
Via Business Wire
What's going on in today's session ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
From CareDx, Inc.
Via Business Wire
News headline image
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
From CareDx, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >